← Back to Search

Working Memory Training in ADHD (The Engage Study)

Phase 1
Waitlist Available
Led By Rosemary Tannock, Ph.D.
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 120 days
Awards & highlights
No Placebo-Only Group

Summary

The overall objective of the current study is to determine whether computerized Working Memory (WM) training will enhance WM capacity in college students with Attention Deficit Hyperactivity Disorder (ADHD). There are also four additional objectives. The first is to investigate whether the program's efficacy is impacted by the duration of the daily training sessions. The second is to determine whether improvements in WM will generalize to secondary outcome tasks, such as inhibitory control and planning. The third objective is to examine whether WM training will also ameliorate ADHD symptoms of inattention and hyperactivity. The last objective is to investigate whether improvements will be maintained at a two month follow-up period. The investigators will also be assessing healthy control participants,who will not be receiving treatment, but will be used as a basis of comparison with the ADHD participants, It is expected that the computerized WM training program will enhance WM capacity in college students with ADHD. In addition, it is believed that these increases in WM capacity will also lead to improvements in other executive functions. It is also hypothesized that WM training will lead to a reduction in ADHD symptomology. Lastly, these improvements should be maintained at three month follow-up.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 120 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 120 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Wechsler Adult Intelligence Scale: Digit Span subtest
Secondary study objectives
'Add-3' working memory test
Adult ADHD Self-Report Scale (ASRS v1.1)
Barkley Deficits in Executive Functioning Scale (BDEFS)
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: 30 Minute TrainingExperimental Treatment1 Intervention
Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
Group II: 15 Minute TrainingExperimental Treatment1 Intervention
Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
Group III: Wait-list ControlActive Control1 Intervention
Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies. After a 5-week period, participants in this arm will have access to the working memory training.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cogmed Working Memory Training Program
2008
N/A
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of TorontoLead Sponsor
721 Previous Clinical Trials
1,115,153 Total Patients Enrolled
6 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
945 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Rosemary Tannock, Ph.D.Principal InvestigatorUniversity of Toronto
~12 spots leftby Dec 2025